Celularity IncNASDAQ:CELUNASDAQ FSI:E. Delinquent (Issuer missed regulatory filing deadline)
- LAST PRICE3.0596
- TODAY'S CHANGE (%)-0.0504 (-1.6206%)
- Bid / Lots3.0600/ 1
- Ask / Lots3.1000/ 1
- Open / Previous Close3.1100 / 3.1100
- Day Range
- 52 Week Range
- Volume2,696
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | CELU |
|---|---|---|
| 09:32 ET | 480 | 3.11 |
| 09:41 ET | 300 | 3.2 |
| 11:02 ET | 300 | 3.1657 |
| 11:08 ET | 100 | 3.08 |
| 11:31 ET | 100 | 3.05 |
| 11:44 ET | 833 | 3.06 |
| 12:39 ET | 110 | 3.0596 |
Today
May 24, 2024
Celularity Inc. Announces Receipt of Nasdaq Notice Regarding Late Form 10-Q Filing, from 5:15PM ET on Friday May 24, 2024 by Dow Jones
5:15PM ET on Friday May 24, 2024 by Dow Jones
May 14, 2024
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Celularity Inc | 67.7M | -0.3x | --- |
Turnstone Biologics Corp | 60.4M | -0.7x | --- |
Gritstone bio Inc | 84.0M | -0.5x | --- |
Prenetics Global Ltd | 73.2M | -1.2x | --- |
Carisma Therapeutics Inc | 55.3M | -0.7x | --- |
Aligos Therapeutics Inc | 46.1M | -0.4x | --- |
Company Information
Celularity Inc. is a clinical-stage biotechnology company. The Company is engaged in developing off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer and immune and infectious diseases. It operates through three business segments: Cell Therapy, Degenerative Disease, and BioBanking. Its therapy product candidates include T cells engineered with a chimeric antigen receptor (CAR), natural killer, cells, mesenchymal-like adherent stromal cells (MLASCs), and exosomes. These therapeutic candidates target indications across cancer, infectious and degenerative diseases. Its cell therapeutic programs include CYCART-19, CYCART-201, CYNK-001, CYNK-301, CYNK-302, APPL-001, and pEXO-001. CYCART-19 is a placental-derived CAR-T cell therapy, in development for the treatment of B-cell malignancies, initially targeting the cluster of differentiation 19. pExo-001 is developed for the treatment of osteoarthritis. APPL-001 is developed for the treatment of Crohn’s disease.
Contact Information
- Headquarters
- 170 Park AveFLORHAM PARK, NJ, United States 07932
- Phone
- 908-768-2170
- Fax
- 302-636-5454
Executives
- Chairman of the Board, Chief Executive Officer
- Robert Hariri
- Chief Financial Officer
- David Beers
- President - Degenerative Disease
- Stephen Brigido
- Senior Executive Vice President, Chief Administrative Officer, General Manager
- John Haines
- Director
- Shiu Fei Ling
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $67.7M |
|---|---|
Revenue (TTM) | $14.8M |
Shares Outstanding | 21.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.44 |
EPS | $-10.51 |
Book Value | $13.36 |
P/E Ratio | -0.3x |
Price/Sales (TTM) | 4.6 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -1,272.09% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
